Diclofenac: 3 agencies, 2005–2018
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 12.9 years separate the first record, 7 Nov 2005 at SMC (Scotland), from the most recent, 17 Oct 2018 at HAS (France).
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — PBAC (Australia), AWMSG (Wales) and TLV (Sweden) among them — hold no record for diclofenac at all.
Not every gap is a refusal: for diclofenac, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
Nothing has been added since 2018; on this evidence the file is dormant.
Against its own class, diclofenac is an outlier: 50% of its decisive outcomes were positive, where molecules sharing ATC class D11A average 75%.
SMC (Scotland) was first to assess diclofenac, on 7 Nov 2005; PHARMAC (New Zealand) did not open a file until 10 May 2012 — a wide spread of 6.5 years between the earliest and latest system to look at it.
3 of the 3 agencies here assessed diclofenac more than once, HAS (France) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 3 of the 18 agencies here have assessed diclofenac.
The full ledger for diclofenac reads 3 recommended, 3 not recommended, 2 other and 1 non-submission, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 17 Oct 2018 | Listing renewal (Transparency Committee) | SMR substantial | source |
| HAS (France) | 22 Jul 2015 | Listing renewal (Transparency Committee) | SMR substantial | source |
| PHARMAC (New Zealand) | 10 May 2012 | Pain | PTAC advice: Not recommended for inclusion (HML) · decision reached | source |
| PHARMAC (New Zealand) | 10 May 2012 | Hospital listing | PTAC advice: Not recommended for inclusion (HML) · decision reached | source |
| SMC (Scotland) | 13 Dec 2010 | For the local symptomatic relief of mild to moderate pain and inflammation following acute blunt trauma of small and medium-sized joints and periarticular structures | not recommended | source |
5 further decisions for diclofenac, across 2 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- dupilumab — same ATC class D11A — Other dermatologicals
- abrocitinib — same ATC class D11A — Other dermatologicals
- nemolizumab — same ATC class D11A — Other dermatologicals
- lebrikizumab — same ATC class D11A — Other dermatologicals
- delgocitinib — same ATC class D11A — Other dermatologicals
- ivermectin — same ATC class D11A — Other dermatologicals
Coverage: 10 decisions for diclofenac from 3 agencies, 2005 to 2018. Data to 7 Sep 2026. ATC class D11A — Other dermatologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.